螺内酯与阿米洛利治疗难治性高血压:一项随机临床试验
该前瞻性、开放标签、盲法终点随机临床试验在韩国14个中心纳入118例经4周固定剂量三联降压药(血管紧张素受体阻滞剂、钙通道阻滞剂、噻嗪类)后家庭收缩压仍≥130 mm Hg的难治性高血压患者,1:1随机接受螺内酯12.5 mg/d(n=60)或阿米洛利5 mg/d(n=58),4周后若家庭收缩压仍≥130 mm Hg且血钾<5.0 mmol/L则分别加量至25 mg/d和10 mg/d。第12周时,阿米洛利组家庭收缩压较基线下降13.6 mm Hg,螺内酯组下降14.7 mm Hg,组间差值-0.68 mm Hg(90% CI,-3.50至2.14 mm Hg),阿米洛利非劣效于螺内酯。两组家庭和诊室收缩压<130 mm Hg达标率无差异,阿米洛利组1例因高钾血症停药,两组均无男性乳房发育。作者认为阿米洛利可作为难治性高血压的有效替代治疗。
要点
- 难治性高血压患者经4周三联降压药后家庭收缩压≥130 mm Hg,可考虑加用阿米洛利5 mg/d或螺内酯12.5 mg/d。
- 第12周家庭收缩压降幅:阿米洛利组-13.6 mm Hg vs 螺内酯组-14.7 mm Hg,组间差值-0.68 mm Hg(90% CI,-3.50至2.14 mm Hg),阿米洛利非劣效于螺内酯。
- 4周后家庭收缩压仍≥130 mm Hg且血钾<5.0 mmol/L时,阿米洛利加量至10 mg/d,螺内酯加量至25 mg/d。
- 家庭收缩压<130 mm Hg达标率:阿米洛利组66.1% vs 螺内酯组55.2%;诊室达标率:57.1% vs 60.3%,两组无差异。
- 阿米洛利组1例因高钾血症停药,两组均无男性乳房发育。
适用人群与场景
- 经4周固定剂量三联降压药(血管紧张素受体阻滞剂、钙通道阻滞剂、噻嗪类)后家庭收缩压≥130 mm Hg的难治性高血压患者。
- 研究纳入患者中位年龄55岁,70%为男性。
诊断标准与关键阈值
- 难治性高血压:经4周固定剂量三联降压药(血管紧张素受体阻滞剂、钙通道阻滞剂、噻嗪类)后家庭收缩压≥130 mm Hg。
- 加量条件:治疗4周后家庭收缩压仍≥130 mm Hg且血清钾<5.0 mmol/L。
处置流程与药物剂量
- 第一步:经4周固定剂量三联降压药后家庭收缩压≥130 mm Hg者,随机接受螺内酯12.5 mg/d或阿米洛利5 mg/d。
- 第二步:治疗4周后若家庭收缩压仍≥130 mm Hg且血清钾<5.0 mmol/L,螺内酯加量至25 mg/d,阿米洛利加量至10 mg/d。
- 目标:家庭收缩压<130 mm Hg。
红旗征与不能漏的情况
- 阿米洛利组1例因高钾血症相关停药。
研究设计与关键结果
- 研究类型:前瞻性、开放标签、盲法终点随机临床试验,在韩国14个中心开展,纳入118例患者。
- 干预与对照:阿米洛利5 mg/d(n=58)vs 螺内酯12.5 mg/d(n=60),4周后按上述条件加量至10 mg/d和25 mg/d。
- 主要终点:第12周家庭收缩压变化组间差值-0.68 mm Hg(90% CI,-3.50至2.14 mm Hg),非劣效界值为置信区间下限-4.4 mm Hg,阿米洛利非劣效于螺内酯。
- 家庭收缩压较基线变化:阿米洛利组-13.6(SD,8.6)mm Hg vs 螺内酯组-14.7(SD,11.0)mm Hg。
- 家庭收缩压<130 mm Hg达标率:阿米洛利组66.1% vs 螺内酯组55.2%;诊室收缩压<130 mm Hg达标率:阿米洛利组57.1% vs 螺内酯组60.3%,两组无差异。
- 不良事件:阿米洛利组1例因高钾血症停药,两组均无男性乳房发育。
- 基线特征:阿米洛利组α受体阻滞剂使用率8.6%,螺内酯组0%,其余人口学特征无差异;基线家庭收缩压阿米洛利组141.5(SD,7.9)mm Hg,螺内酯组142.3(SD,8.5)mm Hg。
证据类型、等级与局限
- 证据类型:随机临床试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于经4周固定剂量三联降压药后家庭收缩压仍≥130 mm Hg的难治性高血压患者,阿米洛利5 mg/d可作为螺内酯12.5 mg/d的替代选择,两者降家庭收缩压效果非劣效。
- 使用阿米洛利需监测血钾,研究中阿米洛利组1例因高钾血症停药。
- 作者认为阿米洛利可作为难治性高血压的有效替代治疗。
指南或共识出处
- ClinicalTrials.gov Identifier: NCT04331691
提炼说明
- 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Amiloride has been proposed as an alternative to spironolactone for treating resistant hypertension. However, no randomized clinical trials have compared the efficacy of spironolactone and amiloride in patients with resistant hypertension.
OBJECTIVE: To determine whether amiloride is noninferior to spironolactone in reducing home-measured systolic blood pressure (SBP) in patients with resistant hypertension.
DESIGN, SETTING, AND PARTICIPANTS: Prospective, open-label, blinded end-point randomized clinical trial conducted at 14 sites in South Korea. From November 16, 2020, to February 29, 2024, 118 patients with home SBP of 130 mm Hg or greater after a 4-week run-in period with a fixed-dose triple medication combination (angiotensin receptor blocker, calcium channel blocker, and thiazide) were enrolled.
INTERVENTION: Patients were randomized in a 1:1 ratio to receive 12.5 mg/d of spironolactone (n = 60) or 5 mg/d of amiloride (n = 58). If home SBP remained 130 mm Hg or greater and serum potassium was less than 5.0 mmol/L after 4 weeks, dosages were increased to 25 mg/d and 10 mg/d, respectively.
MAIN OUTCOMES AND MEASURES: The primary end point was the between-group difference in home SBP change at week 12, with a noninferiority margin of -4.4 mm Hg for the lower bound of the confidence interval. Secondary end points included achievement rates of home- and office-measured SBP of less than 130 mm Hg.
RESULTS: The median age of the study population was 55 years, with 70% male. There were no differences between groups in demographic characteristics other than use of α-blockers (8.6% in the amiloride group and 0% in the spironolactone group). The mean baseline home SBPs were 141.5 (SD, 7.9) mm Hg and 142.3 (SD, 8.5) mm Hg in the amiloride and spironolactone groups, respectively. At week 12, mean home SBP measurements were changed from baseline by -13.6 (SD, 8.6) mm Hg and -14.7 (SD, 11.0) mm Hg in the amiloride and spironolactone groups, respectively (between-group difference in change, -0.68 mm Hg; 90% CI, -3.50 to 2.14 mm Hg), with amiloride demonstrating noninferiority to spironolactone. Home-measured achievement rates of SBP less than 130 mm Hg in the amiloride and spironolactone groups were 66.1% and 55.2%, respectively, and office-measured achievement rates of SBP less than 130 mm Hg were 57.1% and 60.3%, respectively, with no difference between the 2 groups. One case of hyperkalemia-related discontinuation occurred in the amiloride group, with no cases of gynecomastia in either group.
CONCLUSIONS AND RELEVANCE: Amiloride was noninferior to spironolactone in lowering home SBP, suggesting that it could be an effective alternative for treatment of resistant hypertension.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04331691.
参考来源
- Lee CJ, Ihm SH, Shin DH, et al. Spironolactone vs Amiloride for Resistant Hypertension: A Randomized Clinical Trial. JAMA. 2025. PMID: 40366680. doi:10.1001/jama.2025.5129
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。